SCHEMBL5686140

SCHEMBL5686140

Nc1ncc(C(=O)Nc2ccccc2)c(Oc2ccccc2OCc2ccccc2)n1

nearest known ligand 0.59

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SGMS2 Q8NHU3 3/20 0.59
GAA P10253 1/20 0.53
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NPC1 O15118 1/20 0.51
CASP3 P42574 1/20 0.51
RAB9A P51151 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
LRRK2 Q5S007 6/20 0.48
PPIA P62937 1/20 0.46
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5689006 0.87 PTPN11 (0.47) SGMS2GAAMEN1KMT2A
SCHEMBL5686120 0.87 RAB9A (0.53) SGMS2MEN1KMT2ANPC1RAB9A
SCHEMBL4559143 0.81 KMT2A (0.51) MEN1KMT2AALDH1A1
SCHEMBL5686380 0.80 ATR (0.48) SGMS2
SCHEMBL4559637 0.77 PTPN11 (0.45) GAAMEN1KMT2AALDH1A1
SCHEMBL4559175 0.76 MEN1 (0.55) MEN1KMT2ANPC1RAB9A
SCHEMBL875474 0.76 SGMS2 (1.00) SGMS2GAAMEN1KMT2ANPC1
SCHEMBL3979493 0.75 EGFR (0.67) SGMS2GAALRRK2
SCHEMBL11298985 0.74 PTPN11 (0.63) MEN1KMT2AALDH1A1
SCHEMBL16465324 0.71 PRKCI (0.52) MEN1KMT2ANPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP disclosed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO disclosed